Tenaya Therapeutics to Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
Tenaya Therapeutics to Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
An archived replay of the webcast will be available on Tenaya's website.Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET
公司定于12月17日星期二上午8:00（东部时间）召开电话会议
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17.
南旧金山，加利福尼亚州，2024年12月16日（全球新闻电讯）—— Tenaya Therapeutics，Inc.（纳斯达克：TNYA），一家临床阶段的生物技术公司，致力于发现、开发和提供潜在治愈疗法，以解决心脏病的根本原因，将于12月17日星期二宣布TN-201基因治疗在与MYBPC3相关的肥厚性心肌病（HCM）的MyPEAk-1阶段1b/2临床试验中初步的第一组数据。
Conference Call and Webcast
Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register here. The live webcast will be available under the "Events" section of the Investor Relations page of the Tenaya website at investors.tenayatherapeutics.com.
电话会议和网络直播
Tenaya管理团队将于2024年12月17日星期二上午8:00（东部时间）举行网络直播和电话会议，以回顾MyPEAk-1的初步数据。要访问直播，参与者可以在此注册。网络直播将在Tenaya网站的投资者关系页面的“活动”部分提供，网址为investors.tenayatherapeutics.com。
An archived replay of the webcast will be available on Tenaya's website.
网络直播的存档回放将在Tenaya的网站上提供。
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit .
关于Tenaya Therapeutics
Tenaya Therapeutics是一家临床阶段的生物技术公司，致力于一个大胆的使命：发现、开发和提供潜在的治愈疗法，以应对心脏病的根本原因。Tenaya采用一系列整合的内部能力，包括与模式无关的靶标验证、衣壳工程和制造，以生成一系列针对罕见遗传疾病和更普遍的心脏病状况的基因药物。Tenaya的产品线包括TN-201，一种针对MYBPC3相关的肥厚型心肌病（HCM）的基因疗法；TN-401，一种针对PKP2相关的心律失常右心室心肌病（ARVC）的基因疗法；TN-301，一种用于保留射血分数的心力衰竭（HFpEF）的小分子HDAC6抑制剂；以及多个处于早期临床前开发阶段的项目。有关更多信息，请访问。
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Tenaya 联系人
米歇尔·科拉尔
副总裁，企业传播与投资者关系
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
投资者
安妮-玛丽·菲尔兹
精准AQ
annemarie.fields@precisionaq.com
Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com
媒体
温迪·赖安
Ten Bridge 通信董事
wendy@tenbridgecommunications.com
